Requirement for complement in antibody responses is not explained by the classic pathway activator IgM. 2011

Christian Rutemark, and Elisabeth Alicot, and Anna Bergman, and Minghe Ma, and Andrew Getahun, and Stephan Ellmerich, and Michael C Carroll, and Birgitta Heyman
Department of Medical Biochemistry and Microbiology, Uppsala University, BMC, SE-751 23 Uppsala, Sweden.

Animals lacking complement factors C1q, C2, C3, or C4 have severely impaired Ab responses, suggesting a major role for the classic pathway. The classic pathway is primarily initiated by antigen-Ab complexes. Therefore, its role for primary Ab responses seems paradoxical because only low amounts of specific Abs are present in naive animals. A possible explanation could be that the classic pathway is initiated by IgM from naive mice, binding with sufficient avidity to the antigen. To test this hypothesis, a knock-in mouse strain, Cμ13, with a point mutation in the gene encoding the third constant domain of the μ-heavy chain was constructed. These mice produce IgM in which proline in position 436 is substituted with serine, a mutation previously shown to abrogate the ability of mouse IgM to activate complement. Unexpectedly, the Ab response to sheep erythrocytes and keyhole limpet hemocyanin in Cμ13 mice was similar to that in WT mice. Thus, although secreted IgM and the classic pathway activation are both required for the normal primary Ab response, this does not require that IgM activate C. This led us to test Ab responses in animals lacking one of three other endogenous activators of the classic pathway: specific intracellular adhesion molecule-grabbing nonintegrin R1, serum amyloid P component, and C-reactive protein. Ab responses were also normal in these animals.

UI MeSH Term Description Entries
D007148 Immunoglobulin mu-Chains The class of heavy chains found in IMMUNOGLOBULIN M. They have a molecular weight of approximately 72 kDa and they contain about 57 amino acid residues arranged in five domains and have more oligosaccharide branches and a higher carbohydrate content than the heavy chains of IMMUNOGLOBULIN G. Ig mu Chains,Immunoglobulins, mu-Chain,Immunoglobulin mu-Chain,mu Immunoglobulin Heavy Chain,mu Immunoglobulin Heavy Chains,mu-Chain Immunoglobulins,Chains, Ig mu,Immunoglobulin mu Chain,Immunoglobulin mu Chains,Immunoglobulins, mu Chain,mu Chain Immunoglobulins,mu Chains, Ig,mu-Chain, Immunoglobulin,mu-Chains, Immunoglobulin
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D002097 C-Reactive Protein A plasma protein that circulates in increased amounts during inflammation and after tissue damage. C-Reactive Protein measured by more sensitive methods often for coronary heart disease risk assessment is referred to as High Sensitivity C-Reactive Protein (hs-CRP). High Sensitivity C-Reactive Protein,hs-CRP,hsCRP,C Reactive Protein,High Sensitivity C Reactive Protein
D002847 Chromatography, Agarose A method of gel filtration chromatography using agarose, the non-ionic component of agar, for the separation of compounds with molecular weights up to several million. Chromatography, Sepharose,Agarose Chromatography,Sepharose Chromatography,Agarose Chromatographies,Chromatographies, Agarose,Chromatographies, Sepharose,Sepharose Chromatographies
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D003171 Complement Pathway, Classical Complement activation initiated by the binding of COMPLEMENT C1 to ANTIGEN-ANTIBODY COMPLEXES at the COMPLEMENT C1Q subunit. This leads to the sequential activation of COMPLEMENT C1R and COMPLEMENT C1S subunits. Activated C1s cleaves COMPLEMENT C4 and COMPLEMENT C2 forming the membrane-bound classical C3 CONVERTASE (C4B2A) and the subsequent C5 CONVERTASE (C4B2A3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Classical Complement Pathway,Classical Complement Activation Pathway,Complement Activation Pathway, Classical
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D000683 Serum Amyloid P-Component Amyloid P component is a small, non-fibrillar glycoprotein found in normal serum and in all amyloid deposits. It has a pentagonal (pentaxin) structure. It is an acute phase protein, modulates immunologic responses, inhibits ELASTASE, and has been suggested as an indicator of LIVER DISEASE. Amyloid P Component,Amyloid P-Component, Serum,P Component, Amyloid,P-Component, Serum Amyloid,Serum Amyloid P Component
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Christian Rutemark, and Elisabeth Alicot, and Anna Bergman, and Minghe Ma, and Andrew Getahun, and Stephan Ellmerich, and Michael C Carroll, and Birgitta Heyman
April 2020, Plant physiology,
Christian Rutemark, and Elisabeth Alicot, and Anna Bergman, and Minghe Ma, and Andrew Getahun, and Stephan Ellmerich, and Michael C Carroll, and Birgitta Heyman
February 1982, European journal of immunology,
Christian Rutemark, and Elisabeth Alicot, and Anna Bergman, and Minghe Ma, and Andrew Getahun, and Stephan Ellmerich, and Michael C Carroll, and Birgitta Heyman
January 2005, Preventive cardiology,
Christian Rutemark, and Elisabeth Alicot, and Anna Bergman, and Minghe Ma, and Andrew Getahun, and Stephan Ellmerich, and Michael C Carroll, and Birgitta Heyman
January 2023, Frontiers in immunology,
Christian Rutemark, and Elisabeth Alicot, and Anna Bergman, and Minghe Ma, and Andrew Getahun, and Stephan Ellmerich, and Michael C Carroll, and Birgitta Heyman
June 1988, The Journal of experimental medicine,
Christian Rutemark, and Elisabeth Alicot, and Anna Bergman, and Minghe Ma, and Andrew Getahun, and Stephan Ellmerich, and Michael C Carroll, and Birgitta Heyman
January 2008, Blood,
Christian Rutemark, and Elisabeth Alicot, and Anna Bergman, and Minghe Ma, and Andrew Getahun, and Stephan Ellmerich, and Michael C Carroll, and Birgitta Heyman
January 1980, Journal of medical virology,
Christian Rutemark, and Elisabeth Alicot, and Anna Bergman, and Minghe Ma, and Andrew Getahun, and Stephan Ellmerich, and Michael C Carroll, and Birgitta Heyman
January 1978, Immunology,
Christian Rutemark, and Elisabeth Alicot, and Anna Bergman, and Minghe Ma, and Andrew Getahun, and Stephan Ellmerich, and Michael C Carroll, and Birgitta Heyman
March 1980, The Journal of infectious diseases,
Christian Rutemark, and Elisabeth Alicot, and Anna Bergman, and Minghe Ma, and Andrew Getahun, and Stephan Ellmerich, and Michael C Carroll, and Birgitta Heyman
April 1983, Molecular immunology,
Copied contents to your clipboard!